BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 19003540)

  • 1. Management of aggressive pituitary adenomas: current treatment strategies.
    Buchfelder M
    Pituitary; 2009; 12(3):256-60. PubMed ID: 19003540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy of aggressive pituitary tumors.
    Colao A; Grasso LF; Pivonello R; Lombardi G
    Expert Opin Pharmacother; 2011 Jul; 12(10):1561-70. PubMed ID: 21434849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolactinomas in males: any differences?
    Duskin-Bitan H; Shimon I
    Pituitary; 2020 Feb; 23(1):52-57. PubMed ID: 31802331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists.
    Neff LM; Weil M; Cole A; Hedges TR; Shucart W; Lawrence D; Zhu JJ; Tischler AS; Lechan RM
    Pituitary; 2007; 10(1):81-6. PubMed ID: 17285366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Future treatment strategies of aggressive pituitary tumors.
    Lamberts SW; Hofland LJ
    Pituitary; 2009; 12(3):261-4. PubMed ID: 19003539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New medical treatments in pituitary adenomas].
    Drutel A; Caron P; Archambeaud F
    Ann Endocrinol (Paris); 2008 Sep; 69 Suppl 1():S16-28. PubMed ID: 18954854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of NFAs: medical treatment.
    Even-Zohar N; Greenman Y
    Pituitary; 2018 Apr; 21(2):168-175. PubMed ID: 29344905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of cabergoline in a pituitary adenoma secreting follicle-stimulating hormone.
    Leese G; Jeffreys R; Vora J
    Postgrad Med J; 1997 Aug; 73(862):507-8. PubMed ID: 9307745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
    Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
    Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Novel pharmacologic therapies in acromegaly].
    Góth M; Hubina E; Kovács L; Szabolcs I
    Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aggressive prolactinomas: how to manage?
    Lasolle H; Ilie MD; Raverot G
    Pituitary; 2020 Feb; 23(1):70-77. PubMed ID: 31617128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SURGICAL OUTCOMES OF PROLACTINOMAS IN RECENT ERA: RESULTS OF A HETEROGENOUS GROUP.
    Donegan D; Atkinson JL; Jentoft M; Natt N; Nippoldt TB; Erickson B; Meyer F; Erickson D
    Endocr Pract; 2017 Jan; 23(1):37-45. PubMed ID: 27682355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Dopamine Agonist-Resistant Prolactinoma.
    Maiter D
    Neuroendocrinology; 2019; 109(1):42-50. PubMed ID: 30481756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of pituitary adenomas].
    Mezosi E; Nemes O
    Orv Hetil; 2009 Sep; 150(39):1803-10. PubMed ID: 19758960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical management of prolactin-secreting pituitary adenomas.
    Molitch ME
    Pituitary; 2002; 5(2):55-65. PubMed ID: 12675502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical approach to pituitary tumors.
    Neggers SJ; van der Lely AJ
    Handb Clin Neurol; 2014; 124():303-16. PubMed ID: 25248595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperprolactinemia: pathophysiology and management.
    Verhelst J; Abs R
    Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of temozolomide in aggressive pituitary tumors: case report.
    Mohammed S; Kovacs K; Mason W; Smyth H; Cusimano MD
    Neurosurgery; 2009 Apr; 64(4):E773-4; discussion E774. PubMed ID: 19349807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.